Published in Mol Cancer Res on April 01, 2009
Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit? Breast Cancer Res (2009) 1.75
Retracted Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer. Mol Cancer (2013) 1.41
c-Src modulates estrogen-induced stress and apoptosis in estrogen-deprived breast cancer cells. Cancer Res (2013) 1.09
Dynamic, large-scale profiling of transcription factor activity from live cells in 3D culture. PLoS One (2010) 0.97
The impact of adhesion peptides within hydrogels on the phenotype and signaling of normal and cancerous mammary epithelial cells. Biomaterials (2012) 0.93
Crosstalk between PKCα and Notch-4 in endocrine-resistant breast cancer cells. Oncogenesis (2013) 0.91
The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer. Endocr Relat Cancer (2014) 0.90
Responsiveness to PI3K and MEK inhibitors in breast cancer. Use of a 3D culture system to study pathways related to hormone independence in mice. PLoS One (2010) 0.89
PKCα and ERβ Are Associated with Triple-Negative Breast Cancers in African American and Caucasian Patients. Int J Breast Cancer (2012) 0.83
The role of Transposable Elements in shaping the combinatorial interaction of Transcription Factors. BMC Genomics (2012) 0.83
Activation of membrane-associated estrogen receptors decreases food and water intake in ovariectomized rats. Endocrinology (2012) 0.83
Click synthesis of estradiol-cyclodextrin conjugates as cell compartment selective estrogens. Bioorg Med Chem (2009) 0.79
Integration of Downstream Signals of Insulin-like Growth Factor-1 Receptor by Endoplasmic Reticulum Stress for Estrogen-Induced Growth or Apoptosis in Breast Cancer Cells. Mol Cancer Res (2015) 0.76
Novel selective estrogen mimics for the treatment of tamoxifen-resistant breast cancer. Mol Cancer Ther (2014) 0.76
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst (1998) 22.10
Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology (2004) 5.20
Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol Cell (2003) 4.67
Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol (2000) 3.96
Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst (2001) 3.88
Integration of the extranuclear and nuclear actions of estrogen. Mol Endocrinol (2005) 3.44
Protein kinase C isozymes and the regulation of diverse cell responses. Am J Physiol Lung Cell Mol Physiol (2000) 3.13
Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO J (2000) 2.96
Mechanisms of tamoxifen resistance. Endocr Relat Cancer (2004) 2.92
Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. J Natl Cancer Inst (1998) 2.88
ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance. Mol Cell Biol (2004) 2.46
The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J Biol Chem (2001) 2.45
Unraveling the microenvironmental influences on the normal mammary gland and breast cancer. Semin Cancer Biol (2008) 2.41
Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer. J Natl Cancer Inst (2003) 2.18
Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res (2004) 2.15
Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway. J Biol Chem (2000) 2.07
The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci (1993) 2.04
Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements. J Biol Chem (2000) 2.00
Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo. J Natl Cancer Inst (2003) 1.92
Protein kinase C: a target for anticancer drugs? Endocr Relat Cancer (2003) 1.91
HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res (2004) 1.89
High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat (2001) 1.88
Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. Clin Cancer Res (2003) 1.84
Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res (2000) 1.73
Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med (1981) 1.70
Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer (2001) 1.65
Estrogen receptors outside the nucleus in breast cancer. Breast Cancer Res Treat (2007) 1.54
Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst (2000) 1.50
Live and let die: regulatory mechanisms in Fas-mediated apoptosis. Cell Signal (2003) 1.47
Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen. Mod Pathol (2005) 1.40
Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr Relat Cancer (2001) 1.39
Direct binding of syndecan-4 cytoplasmic domain to the catalytic domain of protein kinase C alpha (PKC alpha) increases focal adhesion localization of PKC alpha. J Biol Chem (2003) 1.36
MCF-7 breast cancer cells transfected with protein kinase C-alpha exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. J Clin Invest (1995) 1.36
Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat (1993) 1.36
Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-alpha. J Biol Chem (2006) 1.35
Site-directed perturbation of protein kinase C- integrin interaction blocks carcinoma cell chemotaxis. Mol Cell Biol (2002) 1.35
Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. Clin Cancer Res (1999) 1.32
Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. Breast (2003) 1.32
Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal. J Steroid Biochem Mol Biol (2005) 1.31
Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis. Breast Cancer Res Treat (1999) 1.27
Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. Endocrinology (2000) 1.20
Upregulation of PKC-delta contributes to antiestrogen resistance in mammary tumor cells. Oncogene (2005) 1.18
Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res (1994) 1.17
Apoptotic action of estrogen. Apoptosis (2003) 1.17
Increasing the number of tandem estrogen response elements increases the estrogenic activity of a tamoxifen analogue. Cancer Lett (1995) 1.16
Adaptive hypersensitivity to estrogen: mechanism for sequential responses to hormonal therapy in breast cancer. Clin Cancer Res (2004) 1.15
Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells. Breast Cancer Res Treat (2004) 1.14
Oestrogen receptor: a stable phenotype in breast cancer. Br J Cancer (1996) 1.13
PC cell-derived growth factor mediates tamoxifen resistance and promotes tumor growth of human breast cancer cells. Cancer Res (2004) 1.13
Irreversible loss of the oestrogen receptor in T47D breast cancer cells following prolonged oestrogen deprivation. Br J Cancer (1996) 1.12
ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett (1994) 1.11
Estrogen as therapy for breast cancer. Breast Cancer Res (2002) 1.10
Immunological quantitation of phospholipid/Ca2+-dependent protein kinase of human mammary carcinoma cells: inverse relationship to estrogen receptors. Int J Cancer (1987) 1.10
Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy. J Steroid Biochem Mol Biol (2005) 1.09
Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity. Cell Growth Differ (1996) 1.07
Stable transfection of protein kinase C alpha cDNA in hormone-dependent breast cancer cell lines. Br J Cancer (2000) 1.03
Syndecan-4 regulates localization, activity and stability of protein kinase C-alpha. Biochem J (2004) 1.03
Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase Calpha. Clin Cancer Res (2001) 1.02
Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancer. J Clin Pathol (2007) 1.02
Expression of constitutively active Akt-3 in MCF-7 breast cancer cells reverses the estrogen and tamoxifen responsivity of these cells in vivo. Clin Cancer Res (2003) 0.99
Overexpression of PKCalpha is required to impart estradiol inhibition and tamoxifen-resistance in a T47D human breast cancer tumor model. Carcinogenesis (2006) 0.99
Elevated protein kinase C alpha expression may be predictive of tamoxifen treatment failure. Br J Cancer (2003) 0.98
Normal breast epithelial cells induce apoptosis of breast cancer cells via Fas signaling. Exp Cell Res (2002) 0.94
Fulvestrant ('Faslodex')--a new treatment option for patients progressing on prior endocrine therapy. Endocr Relat Cancer (2002) 0.93
Protein kinase C alpha expression is inversely related to ER status in endometrial carcinoma: possible role in AP-1-mediated proliferation of ER-negative endometrial cancer. Gynecol Oncol (2001) 0.92
Protein Kinase C alpha is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells. Breast Cancer Res Treat (2006) 0.92
Characterization of the estrogen receptor and its dynamics in MCF-7 human breast cancer cells using a covalently attaching antiestrogen. Endocrinology (1984) 0.89
Integrin-protein kinase C relationships. Biochem Soc Trans (2003) 0.89
Designer estrogens. Sci Am (1998) 0.88
Antisense therapy directed to protein kinase C-alpha (Affinitak, LY900003/ISIS 3521): potential role in breast cancer. Semin Oncol (2003) 0.87
Elevated mitogen-activated protein kinase activity in estrogen-nonresponsive human breast cancer cells. Cancer Res (1998) 0.87
Dynamics of estrogen receptor turnover in uterine cells in vitro and in uteri in vivo. Endocrinology (1986) 0.85
Changing role of the oestrogen receptor in the life and death of breast cancer cells. Breast (2003) 0.84
Cross-talk between protein kinase C-alpha (PKC-alpha) and -delta (PKC-delta): PKC-alpha elevates the PKC-delta protein level, altering its mRNA transcription and degradation. Biochemistry (1998) 0.83
Induction of a less aggressive breast cancer phenotype by protein kinase C-alpha and -beta overexpression. Cell Growth Differ (1996) 0.83
Direct binding and activation of protein kinase C isoforms by steroid hormones. Steroids (2008) 0.83
Membrane ERalpha-dependent activation of PKCalpha in endometrial cancer cells by estradiol. Steroids (2008) 0.82
Distinct effects on the conformation of estrogen receptor alpha and beta by both the antiestrogens ICI 164,384 and ICI 182,780 leading to opposite effects on receptor stability. Biochem Biophys Res Commun (1999) 0.82
Sequencing of endocrine therapy in postmenopausal women with advanced breast cancer. Clin Cancer Res (2004) 0.80
Estrogenic and anti-estrogenic regulation of estrogen receptor in MCF-7 breast-cancer cells: comparison of immunocytochemical data with biochemical measurements. Int J Cancer (1998) 0.79
Overexpression of protein kinase C-alpha in MCF-7 breast cancer cells results in differential regulation and expression of alphavbeta3 and alphavbeta5. Int J Oncol (1999) 0.78
Massive estrogen administration in premenopausal women with advanced breast cancer. Cancer Chemother Rep (1962) 0.78
Integrin alpha 5 beta 1 suppresses apoptosis triggered by serum starvation but not phorbol ester in MCF-7 breast cancer cells that overexpress protein kinase C-alpha. Int J Oncol (2001) 0.76
Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res (2008) 2.19
Modulating molecular chaperones improves sensory fiber recovery and mitochondrial function in diabetic peripheral neuropathy. Exp Neurol (2012) 1.59
Retracted Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer. Mol Cancer (2013) 1.41
Gene expression patterns in the human breast after pregnancy. Cancer Prev Res (Phila) (2010) 1.31
An integrated intervention program to control diabetes in overweight Chinese women and men with type 2 diabetes. Asia Pac J Clin Nutr (2008) 0.99
Overexpression of PKCalpha is required to impart estradiol inhibition and tamoxifen-resistance in a T47D human breast cancer tumor model. Carcinogenesis (2006) 0.99
LFA-1 and VLA-4 involved in human high proliferative potential-endothelial progenitor cells homing to ischemic tissue. Thromb Haemost (2006) 0.97
C-terminal heat shock protein 90 inhibitor decreases hyperglycemia-induced oxidative stress and improves mitochondrial bioenergetics in sensory neurons. J Proteome Res (2012) 0.96
Thiazole antibiotics against breast cancer. Cell Cycle (2010) 0.93
PTK6 activation at the membrane regulates epithelial-mesenchymal transition in prostate cancer. Cancer Res (2013) 0.92
Targeting the heat shock protein 90 dimer with dimeric inhibitors. J Med Chem (2011) 0.91
Heat shock protein 70 is necessary to improve mitochondrial bioenergetics and reverse diabetic sensory neuropathy following KU-32 therapy. J Pharmacol Exp Ther (2013) 0.87
Stable transfection of an estrogen receptor beta cDNA isoform into MDA-MB-231 breast cancer cells. J Steroid Biochem Mol Biol (2003) 0.86
Gene therapy for rheumatoid arthritis: recent advances. Curr Gene Ther (2008) 0.83
The effect of the phytoestrogens genistein, daidzein, and equol on the growth of tamoxifen-resistant T47D/PKC alpha. Nutr Cancer (2007) 0.83
Novel C-terminal Hsp90 inhibitor for head and neck squamous cell cancer (HNSCC) with in vivo efficacy and improved toxicity profiles compared with standard agents. Ann Surg Oncol (2011) 0.82
Exploiting conformational dynamics in drug discovery: design of C-terminal inhibitors of Hsp90 with improved activities. J Chem Inf Model (2014) 0.81
Induction of heat shock protein 70 (Hsp70) prevents neuregulin-induced demyelination by enhancing the proteasomal clearance of c-Jun. ASN Neuro (2012) 0.81
Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites. Chem Res Toxicol (2003) 0.80
Syntheses, molecular targets and antitumor activities of novel triptycene bisquinones and 1,4-anthracenedione analogs. Anticancer Agents Med Chem (2006) 0.80
Total syntheses of (+/-)-ovalicin, C4(S *)-isomer, and its C5-analogs and anti-trypanosomal activities. Bioorg Med Chem (2008) 0.79
Identification of novel RARbeta2 transcript variants with short 5'-UTRs in normal and cancerous breast epithelial cells. Oncogene (2005) 0.79
Click synthesis of estradiol-cyclodextrin conjugates as cell compartment selective estrogens. Bioorg Med Chem (2009) 0.79
Antitumor triptycene analogs directly interact with isolated mitochondria to rapidly trigger markers of permeability transition. Anticancer Res (2007) 0.79
Development of a high-throughput screening cancer cell-based luciferase refolding assay for identifying Hsp90 inhibitors. Assay Drug Dev Technol (2013) 0.78
Highly selective antibacterial activities of silver nanoparticles against Bacillus subtilis. J Nanosci Nanotechnol (2013) 0.78
Novel substituted 1,4-anthracenediones with antitumor activity directly induce permeability transition in isolated mitochondria. Int J Oncol (2007) 0.77
Comparison of patient survival between hemodialysis and peritoneal dialysis in a single Chinese center. Int Urol Nephrol (2014) 0.76
Antitumor triptycene analogs induce a rapid collapse of mitochondrial transmembrane potential in HL-60 cells and isolated mitochondria. Int J Oncol (2006) 0.75
Time-dependent evolution of the Bi(3.64)Mo(0.36)O(6.55)/Bi2MoO6 heterostructure for enhanced photocatalytic activity via the interfacial hole migration. Nanoscale (2015) 0.75
Development of Phenyl Cyclohexylcarboxamides as a Novel Class of Hsp90 C-terminal Inhibitors. Chemistry (2017) 0.75
Size-tunable fabrication of multifunctional Bi2O3 porous nanospheres for photocatalysis, bacteria inactivation and template-synthesis. Nanoscale (2014) 0.75
Effects of human yolk sac endothelial cells on supporting expansion of hematopoietic stem/progenitor cells from cord blood. Cell Biol Int (2006) 0.75
Survival rates in patients with diabetes on peritoneal dialysis in China. Ren Fail (2013) 0.75